Developing antibodies with tailored immune functions for autoimmune diseases
Antibodies direct immune responses through their constant region, the Fc domain. Overlapping receptor-binding sites make it difficult to engineer antibodies that engage specific combinations of immune receptors. This limits precise control of downstream immunity.
Fy Cappa Biologics is developing antibody medicines for autoimmune and inflammatory diseases. Its machine-learning platform designs the region that controls immune activity, creating engineered parts for use in existing or new antibody therapies.
What stands out about Fy Cappa Biologics
Demonstrated accurate prediction of Fc-receptor binding from antibody sequences in co-founders' 2025 Fc-engineering research.
Source ↗Fy Cappa Biologics founders Sai Reddy and Andre Mercanzini previously co-founded deepCDR Biologics, which was acquired by Alloy Therapeutics in 2021.
Source ↗Brings ETH Zurich immunology expertise through co-founder Sai Reddy, a bioengineering PhD and professor.
Source ↗Spun out of Sai Reddy’s Systems and Synthetic Immunology laboratory at ETH Zurich.
Source ↗Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.